You can buy or sell RGLS and other stocks, options, ETFs, and crypto commission-free!
Regulus Therapeutics Inc. Common Stock, also called Regulus Therapeutics, is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Read More Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. The company was founded in September 2007 and is headquartered in San Diego, CA.
San Diego, California
52 Week High
52 Week Low
PR NewswireMar 18
Regulus Reports Fourth Quarter and Year-End 2018 Financial Results and Recent Updates
LA JOLLA, Calif., March 18, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth quarter and year ended December 31, 2018 and provided a corporate update. "2018 was a challenging year for Regulus, but I am encouraged by our program advancements and recent corporate and cost-saving efforts. Importantly, we have nearly completed the trans...
Markets InsiderMar 15
Regulus Announces Transition of Research Leadership
LA JOLLA, Calif., March 15, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the resignation of Dr. Timothy Wright, Chief Research and Development Officer, effective March 15, 2019. Dr. Wright is leaving for personal reasons to pursue a new opportunity, and will continue to support Regulus as a scientific advisor. "We appreciate Tim's contributions over the last t...
Simply Wall StMar 13
Did You Manage To Avoid Regulus Therapeutics’s (NASDAQ:RGLS) 99% Share Price Wipe Out?
Regulus Therapeutics Inc. (NASDAQ:RGLS) shareholders will doubtless be very grateful to see the share price up 41% in the last month. But will that heal all the wounds inflicted over 5 years of declines? Unlikely. In fact, the share price has tumbled down a mountain to land 99% lower after that period. It’s true that the recent bounce could signal the company is turning over a new leaf, but we are not so sure. The important question is if the business itself justifies a higher share price in the long term. ...
-$0.92 per share
-$0.98 per share